Dengue Vaccines Market Size to Reach US$ 1.3 Billion by 2030
The dengue vaccines market reached size is expected to reach over US$ 1.3 billion by 2030 from US$ 0.4 Bn in 2020, expanding growth at a CAGR of 11.2% from 2021 to 2030.
Dengue is a mosquito-borne tropical disease caused by dengue virus. Symptoms usually begin three to 14 days after infection. These include high fever, vomiting, headache, muscle & joint pain, and a characteristic skin rash. A vaccine to prevent dengue (Dengvaxia) has been licensed, and is available in some countries for people aged between nine and 45 years. The World Health Organization recommends that the vaccine should only be given to persons with confirmed prior history of dengue virus infection. The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not previously infected by the virus could be at risk of developing severe dengue, if they are infected after being vaccinated.
Disrupted sanitation services and curtailed water supply lead to conditions that assist mosquito breeding and proliferation, while warm temperatures lead to longer active season for mosquitos. Climate change is likely to increase the burden of dengue, which, in turn, is anticipated to boost the growth of the global dengue vaccines market.
The market in Asia Pacific is expected to expand at a high CAGR from 2021 to 2030, owing to highly developed healthcare sector, rise in prevalence of dengue, and continuous evolution of dengue vaccines. The region offers significant opportunities in the dengue vaccines market.
R&D Becomes Deciding Factor for Greater Acceptability of Dengue Vaccines
The commitment to R&D for vaccine development is emerging as one of the most crucial strategies to gain a competitive edge in the dengue vaccines market. Continuous research holds promising potentials for the development of next-gen dengue, malaria, and tuberculosis vaccines. The R&D has become the need of the hour, since greater acceptability, improved production, and cost effectiveness of dengue vaccines are key deciding factors for its success in the market landscape.
The Developing Countries Vaccine Manufacturers Network (DCVMN) is gaining popularity for its growing capacity and willingness to effectively advance vaccine clinical development. Network members linked with the dengue vaccines market are boosting their production capacities to combat high incidence of dengue and other regional infectious diseases in patients.
Access to Safe, Effective Dengue Vaccine Candidates Benefits Endemic Countries
According to the World Health Organization (WHO), dengue represents one of the 10 biggest global health threats. Panacea Biotec - a global generic and specialty pharmaceutical and vaccine maker registered in India has announced the successful completion of phase I/II study of its novel tetravalent recombinant chimeric dengue candidate vaccine DengiAll. Companies in the dengue vaccines market are taking cues from such news, and making efforts to increase access to safe and effective dengue vaccine candidates to minimize the devastating impact of dengue fever in endemic countries such as Colombia, Sri Lanka, and Argentina.
Companies in the dengue vaccines market are innovating in vaccine candidates that induce robust, balanced, and neutralizing antibody response against all four dengue virus serotypes.
Report Highlights
In terms of category, the live attenuated vaccines segment accounted for 33% share of the global market in 2020. The segment is anticipated to expand at a CAGR of 9.8% from 2021 to 2030.
In terms of product, the global dengue vaccines market has been bifurcated into CYD-TDV (Dengvaxia) and others. The CYD-TDV (Dengvaxia) segment accounted for 97.60% share of the market in 2020. The segment is likely to expand at a CAGR of 10.80% from 2021 to 2030.
Based on route of administration, the global dengue vaccines market has been classified into subcutaneous and others. The subcutaneous segment accounted for 75.50% share of the market in 2020. The segment is projected to expand at a CAGR of 11.2% from 2021 to 2031. Dengvaxia is given by the doctor or nurse as an injection underneath the skin (subcutaneous route) in the upper arm. Adults or children will receive three injections of 0.5 mL each at 6-month intervals. Currently, Dengvaxia is the only approved drug for dengue, which is used in dengue treatment.
In terms of end user, the global dengue vaccines market has been divided into hospitals, government institutes, specialty clinics, and others. The hospitals segment dominated the global market in 2020. The segment is anticipated to reach US$ 1.1 Bn by 2030.
In terms of region, the Asia Pacific dominated the global dengue vaccines market in 2020, followed by Latin America. Asia Pacific’s significant market share can be ascribed to presence of a large number of key players, rise in prevalence of dengue, improving healthcare infrastructure, and funding from governments and large corporates. Brazil and Mexico are the leading markets in the region, due to the rise in investment in development of well-equipped health care institutions and rise in prevalence of dengue cases.
Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global dengue vaccines market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
The global dengue vaccines market is fragmented in terms of number of players. Key players operating in the global market include Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck Co. & Inc., GlaxoSmithKline plc, GeneOne Life Science, Medigen Vaccine Biologics, Panacea Biotec Limited, Sun Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Biological E, and VabioTech.
Market Segmentation
By Category
By Product
By Route of Administration
By End User
By Region
This report focuses on dengue vaccines market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall dengue vaccines market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global dengue vaccines market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global dengue vaccines market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the dengue vaccines market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
In this study, the years considered to estimate the market size of dengue vaccines are as follows:
Research Methodology
The research methodology adopted by analysts for compiling the global dengue vaccines market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global dengue vaccines market.
The study objectives of this report are:
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers